NextCure presented promising preclinical data on NC605, an antibody that enhances bone quality in Osteogenesis Imperfecta.
Quiver AI Summary
NextCure, Inc. has announced promising preclinical data showcasing the efficacy of its novel anti-Siglec-15 antibody, NC605, in treating Osteogenesis Imperfecta (OI), a brittle bone disease. In an oral presentation at the Osteogenesis Imperfecta Federation Europe virtual meeting, the company highlighted that treatment with NC605 led to improved bone quality and mechanical properties in a model of OI. Key results showed a significant reduction in fracture incidence in treated mice, with 90% of male and 80% of female subjects experiencing no fractures, compared to lower rates in control groups. Furthermore, treated mice exhibited enhanced bone mineral density and quality, suggesting the potential of NC605 as a transformative therapy for OI patients. The research was carried out in collaboration with Dr. Cathleen Raggio from the Hospital for Special Surgery in New York.
Potential Positives
- NextCure's NC605 shows promise as a transformative treatment for Osteogenesis Imperfecta, indicating potential therapeutic advancements in a rare disorder with no current cure.
- The preclinical data demonstrates significant improvements in bone quality and mechanical properties in treated OI mice, suggesting a novel mechanism of action that differentiates NC605 from existing treatments.
- 90% of male and 80% of female treated OI mice exhibited no fractures, marking a substantial improvement over control groups and indicating the effectiveness of NC605.
- The collaboration with Dr. Cathleen Raggio enhances credibility and highlights NextCure's commitment to advancing innovative research in the field of bone disorders.
Potential Negatives
- NextCure has no approved products for commercial sale, highlighting its vulnerable position as a clinical-stage biopharmaceutical company.
- The press release emphasizes the company's history of significant losses, which raises concerns about its financial stability and ability to sustain operations without obtaining additional financing.
- Forward-looking statements regarding clinical development are accompanied by substantial risks and uncertainties, suggesting that the positive early data may not translate into successful clinical outcomes or market approval.
FAQ
What is NC605 and its significance in treating Osteogenesis Imperfecta?
NC605 is a novel anti-Siglec-15 antibody shown to enhance bone quality and reduce fracture incidence in Osteogenesis Imperfecta models.
What were the key findings from the NC605 study presented by NextCure?
The study found that NC605 treatment led to improved mechanical properties of bones with significantly reduced fracture rates in treated mice.
How does NC605 differ from current OI treatments?
Unlike current anti-resorptive treatments, NC605 inhibits bone loss while enhancing osteoblast recruitment, resulting in higher quality bone formation.
What impact does NC605 have on fracture incidence in Osteogenesis Imperfecta models?
NC605 treatment resulted in 90% of male and 80% of female OI mice having no fractures, significantly higher than control groups.
Who collaborated with NextCure on the NC605 research?
The data was generated in collaboration with Dr. Cathleen Raggio from the Hospital for Special Surgery, New York.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NXTC Hedge Fund Activity
We have seen 10 institutional investors add shares of $NXTC stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AFFINITY ASSET ADVISORS, LLC added 614,643 shares (+36.4%) to their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC removed 386,221 shares (-84.3%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 233,096 shares (-80.6%) from their portfolio in Q3 2024
- ASSENAGON ASSET MANAGEMENT S.A. removed 99,178 shares (-53.8%) from their portfolio in Q3 2024
- HUDSON BAY CAPITAL MANAGEMENT LP removed 96,128 shares (-47.2%) from their portfolio in Q3 2024
- ARMISTICE CAPITAL, LLC added 64,000 shares (+177.8%) to their portfolio in Q3 2024
- TWO SIGMA ADVISERS, LP removed 57,700 shares (-100.0%) from their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) --
NextCure, Inc.
(Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, in an oral presentation at the Osteogenesis Imperfecta Federation Europe virtual Investigator Meeting on November 15
th
, 2024. These results demonstrate that NC605 is a highly effective treatment for Osteogenesis Imperfecta (OI), also known as brittle bone disease in a well-established model of disease.
OI is a rare disorder that results in high bone turnover, abnormal bone formation, bone fragility and recurrent fractures. There is no cure for OI. Current anti-resorptive treatments inhibit both bone loss and bone formation leading to an increase in bone density, but overall poor bone quality. In contrast, NC605 inhibits bone loss and enhances osteoblast recruitment, to produce new bone, resulting in the generation of quality bone with increased density.
Fracture incidence and bone quality were assessed in male and female OI mice (
oim
) treated with 20 mg/kg of surrogate antibody NP159 (murine mAb parent to NC605) and compared to control groups. Key findings include:
In the treated mice, 90% of male
oim
and 80% of female
oim
, had no fractures post-sacrifice, compared to 85% and 55% in the control groups, respectively.
For the treated
oim
population, both sexes showed:
Increased trabecular and cortical tissue mineral density.
Increased cortical bone mineral density.
Collectively, all changes resulted in overall enhanced bone quality with better mechanical properties.
In contrast, only the treated male
oim
population showed:
Increased trabecular bone volume fraction, including an increase in the number of trabeculae and a decreased separation between trabeculae.
Increased cortical thickness.
Collectively, the changes resulted in an increase of max load and stiffness, measures of mechanical bone strength.
"We have again demonstrated that, NP159, a surrogate murine antibody for NC605, reduces fracture incidence in both male and female OI mice. Given sexual dimorphism seen with OI, we noted improved bone quality in the treated male mice specifically," said Solomon Langermann, Ph.D., NextCure's chief scientific officer. "We continue to believe that NC605 has the potential to be a transformative agent for both female and male OI patients."
The data were generated in collaboration with Dr. Cathleen Raggio, Hospital for Special Surgery, New York.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response.
Cautionary Statement Regarding Forward-Looking Statements
Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," "hope," "forward" and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and NextCure's dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com